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Background
For a patient with Hereditary Angioedema (HAE), physio-
logical and/or psychological stress can cause insufficient
control of local inflammatory pathways. This leads to
complement and contact system activation and excess bra-
dykinin resulting in angioedema. Therefore, an invasive
procedure or surgery can trigger an HAE attack; this in
turn can cause further medical complications and pose an
added danger to the post-procedure patient. C1 inhibitor,
Berinert®, was approved in the US and Canada in 2009
and 2010, respectively, for the treatment of acute attacks.
In April 2013, Berinert® was approved in Europe for
short-term prophylaxis prior to medical, dental, or surgical
procedures to prevent HAE attacks. Currently, Berinert® is
not approved in Canada or the US for prophylaxis. We
aim to demonstrate the effectiveness of C1 esterase inhibi-
tor, Berinert®, as a prophylactic treatment for HAE
patients undergoing invasive procedures.
Method
A retrospective chart review from our Canadian Tertiary
Care Allergy and Asthma Clinic of our entire database
of HAE patients was performed.
Results
Between 1997 and June 2014, C1 esterase inhibitor for
prophylactic use was administered prior to invasive pro-
cedures. There were a total of 28 procedures, performed
on 15 patients.
The 28 procedures breakdown as follows: 9 dental
surgeries, 3 open heart surgeries, 8 other surgical proce-
dures, 3 child birth, 5 invasive procedures
In all 28 procedures, there was no incidence of post-
procedure HAE attacks after prophylactic administration
of C1 esterase inhibitor.
Conclusion
We found that C1 esterase inhibitor decreased the inci-
dence of post-procedure HAE attacks and was an effec-
tive prophylactic treatment.
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